Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

Sanofi is harnessing the power of pop music to boost awareness of the experience of living with Type 1 diabetes. The French drugmaker has sponsored the formation of a new girl group, dubbed 1Type ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

PARIS and NEW YORK and SAN FRANCISCO, Nov. 12, 2024 /PRNewswire/ -- Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and ...

PARIS and NEW YORK and SAN FRANCISCO, Nov. 12, 2024 /PRNewswire/ -- Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and ...